Zoetis Inc. is a leading animal health company with a market capitalization of nearly $53.8 billion, operating in 45 countries. Despite recent struggles, its stock has fallen 32.4% from its peak in 2024 and is trading below key moving averages. Q3 earnings saw a 13.8% drop due to a softening demand outlook.

However, Zoetis regained momentum after being initiated with a “Sector Weight” rating, with analysts expecting it to outperform. Comparatively, its rival Dr. Reddy’s Laboratories Limited has also faced challenges. Despite a consensus “Moderate Buy” rating, analysts believe Zoetis can reach new highs, with a mean price target of $172.28, a 40.2% premium.

Read more at Yahoo Finance: Is Zoetis Stock Underperforming the Dow?